Regulatory T cells participate in the recovery of ischemic stroke patients
Santamaría Cadavid, María; Rodriguez Castro, Emillio Francisco; Rodríguez Yáñez, Manuel; Arias Rivas, Susana; López Dequidt, Iria Alejandra; Pérez Mato, María; Rodríguez Pérez, Manuel; López Loureiro, Ignacio; Hervella ., Pablo; Campos Pérez, Francisco; Castillo Sánchez, José; Iglesias Rey, Ramón; Sobrino Moreiras, Tomas
Identificadores
Identificadores
Visualización ou descarga de ficheiros
Visualización ou descarga de ficheiros
Data de publicación
2020Título da revista
BMC Neurology
Tipo de contido
Journal Article
DeCS
interleucina-10 | anciano | isquemia cerebral | factores de riesgo | linfocitos T | mediana edad | accidente cerebrovascular | humanosMeSH
Risk Factors | Middle Aged | Humans | T-Lymphocytes | Interleukin-10 | Brain Ischemia | Stroke | AgedResumo
BACKGROUND: Recent preclinical studies have shown that regulatory T cells (Treg) play a key role in the immune response after ischemic stroke (IS). However, the role of Treg in human acute IS has been poorly investigated. Our aim was to study the relationship between circulating Treg and outcome in human IS patients. METHODS: A total of 204 IS patients and 22 control subjects were recruited. The main study variable was good functional outcome at 3 months (modified Rankin scale </=2) considering infarct volume, Early Neurological Deterioration (END) and risk of infections as secondary variables. The percentage of circulating Treg was measured at admission, 48, 72 h and at day 7 after stroke onset. RESULTS: Circulating Treg levels were higher in IS patients compared to control subjects. Treg at 48 h were independently associated with good functional outcome (OR, 3.5; CI: 1.9-7.8) after adjusting by confounding factors. Patients with lower Treg at 48 h showed higher frequency of END and risk of infections. In addition, a negative correlation was found between circulating Treg at 48 h (r = - 0.414) and 72 h (r = - 0.418) and infarct volume. CONCLUSIONS: These findings suggest that Treg may participate in the recovery of IS patients. Therefore, Treg may be considered a potential therapeutic target in acute ischemic stroke.